TEVA PHARMACEUTICAL INDUSTRIES LIMITED Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $55.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-03
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $55.00M, a 64.52% decline from fiscal 2024.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $155.00M, a 1191.67% increase from fiscal 2023.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $12.00M, a 500.00% increase from fiscal 2022.
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $2.00M, a 94.59% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 0 month | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|---|
| 2025-12-31 | $55.00M 10-K · filed 2026-02-03 | |
| 2024-12-31 | $155.00M 10-K · filed 2026-02-03 | |
| 2023-12-31 | $12.00M 10-K · filed 2026-02-03 | |
| 2022-12-31 | $2.00M 10-K · filed 2025-02-05 | |
| 2021-12-31 | $37.00M 10-K · filed 2024-02-12 | |
| 2020-12-31 | $9.00M 10-K · filed 2023-02-10 | |
| 2019-12-31 | $33.00M 10-K · filed 2022-02-09 | |
| 2018-12-31 | $19.00M 10-K · filed 2021-02-10 | |
| 2017-12-31 | $29.00M 10-K · filed 2018-02-12 | $29.00M 10-K · filed 2020-02-21 |
| 2016-12-31 | -$18.00M 10-K · filed 2018-02-12 | $18.00M 10-K · filed 2019-02-19 |
| 2015-12-31 | $14.00M 10-K · filed 2018-02-12 | |
| 2014-12-31 | $12.00M 20-F · filed 2017-02-15 | |
| 2013-12-31 | $69.00M 20-F · filed 2016-02-11 | |
| 2012-12-31 | $29.00M 20-F · filed 2015-02-09 | |
| 2011-12-31 | $21.00M 20-F · filed 2014-02-10 | |
| 2010-12-31 | $25.00M 20-F · filed 2013-02-12 | |
| 2009-12-31 | $31.00M 20-F · filed 2012-02-17 | |
| 2008-12-31 | $18.00M 20-F · filed 2011-02-15 |